Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 5/20 | 0.44 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882366 | 1.00 | FPR1 (0.44) | FPR1FPR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4882358 | 1.00 | FPR1 (0.44) | FPR1FPR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4884911 | 0.90 | FPR1 (0.44) | FPR1FPR2HTR2CHTR2BHTR6 | |
| SCHEMBL4884898 | 0.90 | FPR1 (0.44) | FPR1FPR2HTR2CHTR2BHTR6 | |
| SCHEMBL4884905 | 0.90 | FPR1 (0.44) | FPR1FPR2HTR2CHTR2BHTR6 | |
| SCHEMBL4890968 | 0.86 | CHRNB2 (0.40) | FPR1FPR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4890979 | 0.86 | CHRNB2 (0.40) | FPR1FPR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4890972 | 0.86 | CHRNB2 (0.40) | FPR1FPR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4925657 | 0.85 | GRM2 (0.43) | FPR1FPR2SSTR1SSTR4HTR2C | |
| SCHEMBL4925663 | 0.85 | GRM2 (0.43) | FPR1FPR2SSTR1SSTR4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | FPR1 4794/4885FPR2 4698/4885CHRNB2 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.